Key takeaways
- • Frequency: Uncommon — 3-7% in trials.
- • Trial reference: STEP-1 (semaglutide) (3-7%).
- • Management: typically resolves within 4-8 weeks as the body adapts.
- • When to call doctor: see red-flag list below.
Why this happens
Rapid weight loss + protein/micronutrient shifts cause more hair follicles to enter the resting (telogen) phase simultaneously. The shedding shows up 2-4 months later. Hair regrowth is the norm.
How to manage it
- Hit daily protein target (1.2-1.6g/kg body weight) — protein deficiency exacerbates shedding
- Iron, ferritin, vitamin D, B12, zinc panels — deficiencies amplify hair loss
- Biotin supplements have weak evidence; protein adequacy matters more
- Avoid harsh hair treatments + tight hairstyles during shedding phase
- Telogen effluvium resolves naturally — hair density returns 6-12 months after weight stabilizes
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • Patchy hair loss (distinct bald spots) — different condition (alopecia areata, traction)
- • Hair loss + skin changes (lupus, thyroid disorders)
- • No regrowth after 12 months of weight stabilization
- • Family history of androgenic alopecia — different treatment path
Drug-specific notes
- Wegovy: Alopecia ~3% in STEP-1; ~5-7% in larger commercial use surveys
- Zepbound: Similar rates to semaglutide
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Diarrhea on GLP-1 medications
Gastrointestinal
Constipation on GLP-1 medications
Systemic
Fatigue on GLP-1 medications
Neurological
Headache on GLP-1 medications
Gastrointestinal
Gallbladder issues on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)